Article Information
History
- September 27, 2020.
Article Versions
- Version 1 (March 24, 2020 - 07:39).
- Version 2 (July 15, 2020 - 00:24).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Huijie Bian*,#,1,
- Zhao-Hui Zheng*,2,
- Ding Wei*,1,
- Zheng Zhang*,1,
- Wen-Zhen Kang*,3,
- Chun-Qiu Hao*,3,
- Ke Dong4,
- Wen Kang3,
- Jie-Lai Xia5,
- Jin-Lin Miao1,
- Rong-Hua Xie2,
- Bin Wang1,
- Xiu-Xuan Sun1,
- Xiang-Min Yang1,
- Peng Lin1,
- Jie-Jie Geng1,
- Ke Wang1,
- Hong-Yong Cui1,
- Kui Zhang2,
- Xiao-Chun Chen6,
- Hao Tang6,
- Hong Du3,
- Na Yao3,
- Shuang-Shuang Liu6,
- Lin-Na Liu7,
- Zhe Zhang3,
- Zhao-Wei Gao3,
- Gang Nan1,
- Qing-Yi Wang8,
- Jian-Qi Lian#,3,
- Zhi-Nan Chen#,1 and
- Ping Zhu#,2
- 1National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi’an 710032, China
- 2Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China
- 3Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
- 4Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
- 5College of Military Preventive Medicine, Fourth Military Medical University, Xi’an 710032, China
- 6Jiangsu Pacific Meinuoke Biopharmceuticals Co. Ltd. Changzhou 213022, China
- 7Department of Pharmaceutics, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
- 8Department of Foreign Languages, Fourth Military Medical University, Xi’an 710032, China
- ↵## Correspondence to: Prof. Ping Zhu, Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China. Tel: +86-29-84771581, E-mail: zhuping{at}fmmu.edu.cn, Prof. Zhi-Nan Chen, National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi’an 710032, China. Tel: +86-29-84773243, E-mail: znchen{at}fmmu.edu.cn, Prof. Huijie Bian, National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi’an 710032, China. Tel: +86-29-84774480, E-mail: hjbian{at}fmmu.edu.cn, Prof. Jian-Qi Lian, Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China. Tel: +86-29-84777452, E-mail: lianjq{at}fmmu.edu.cn
↵* These authors contributed equally to this work.
Posted September 27, 2020.
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
